InsidersTradesSigma
Follow the Iovance Biotherapeutics, INC. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Health Care sector, Iovance Biotherapeutics, INC. has logged 120 reports. Market capitalisation: €3.6bn. The latest transaction was reported on 10 September 2026 (Levée d'options). Among the most active insiders: BILINSKY IGOR. Every trade is openly available.
120
Insider Decl.
n/a
Thresholds
€135m
19 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Iovance Biotherapeutics, INC. Buy (bullish), based on 9 analysts. Average price target: US$10.00.
35Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,040 of 29,064 companies
22.3
score / 100
Value16
Quality28
FCF yld-9.3%
Earn yld-11%
EV/EBITDA·
ROE-40%
Gross mgn34%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 10 September 2026
Declarations120 total
7,813 shares0Common StockSEC:0001104659-26-106750:0
3,976 shares@ US$8.70Common StockSEC:0001104659-26-106750:1
9,766 shares0Common StockSEC:0001104659-26-106748:0
4,478 shares@ US$8.70Common StockSEC:0001104659-26-106748:1
15,626 shares0Common StockSEC:0001104659-26-106752:0
6,638 shares@ US$8.70Common StockSEC:0001104659-26-106752:1
4,472 shares@ US$8.280.0010% mcap46.4% of flowCommon StockSEC:0001104659-26-105099:1
8,789 shares0Common StockSEC:0001104659-26-105099:0
5,470 shares0Common StockSEC:0001104659-26-105100:0
2,508 shares@ US$8.280.0006% mcap67.4% of flowCommon StockSEC:0001104659-26-105100:1
17,702 shares@ US$8.280.0040% mcap71.8% of flowCommon StockSEC:0001104659-26-105101:1
41,669 shares0Common StockSEC:0001104659-26-105101:0
2,436 shares@ US$6.400.0004% mcap21.9% of flowCommon StockSEC:0001104659-26-095040:1
10,001 shares0Common StockSEC:0001104659-26-095040:0
21,238 shares@ US$6.210.0037% mcap100.0% of flowCommon StockSEC:0001104659-26-093482:1
49,995 shares0Common StockSEC:0001104659-26-093482:0
7,813 shares0Common StockSEC:0001104659-26-071891:0
7,813 shares0Common StockSEC:0001104659-26-071897:0
3,976 shares@ US$4.230.0005% mcap39.3% of flowCommon StockSEC:0001104659-26-071891:1
3,976 shares@ US$4.230.0005% mcap100.0% of flowCommon StockSEC:0001104659-26-071897:1
4,473 shares@ US$3.9668.2% of flowCommon StockSEC:0001104659-26-070149:1
8,790 shares0Common StockSEC:0001104659-26-070149:0
62,493 shares0Common StockSEC:0001104659-26-024765:0
31,246 shares0Common StockSEC:0001104659-26-024762:0
39,059 shares0Common StockSEC:0001104659-26-024760:0
25 of 120 declarations
关于 Iovance Biotherapeutics, INC.
Iovance Biotherapeutics, INC. 是一家生物制药公司，专注于开发癌症治疗的细胞疗法。它专门利用改良的T细胞来靶向和摧毁肿瘤细胞。